Mosnodenvir (JNJ-1802), a pan-serotype dengue antiviral agent, exhibits picomolar to low nanomolar in vitro activity with a high barrier to resistance and is safe and well-tolerated in murine models [1] [2]. It functions by blocking the NS3-NS4B interaction within the viral replication complex.